Qiagen (NASDAQ:QGEN)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank in a research note issued on Friday.

QGEN has been the subject of a number of other research reports. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Cowen restated a “hold” rating and set a $33.00 price objective on shares of Qiagen in a report on Monday, August 14th. Zacks Investment Research cut Qiagen from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. BidaskClub downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Finally, Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Thursday, August 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $34.06.

Shares of Qiagen (QGEN) opened at $31.90 on Friday. The stock has a market capitalization of $7,323.83, a PE ratio of 26.15, a PEG ratio of 1.97 and a beta of 1.13. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The company had revenue of $364.00 million during the quarter, compared to the consensus estimate of $363.42 million. During the same quarter in the prior year, the company posted $0.29 EPS. The firm’s revenue was up 7.5% on a year-over-year basis. research analysts expect that Qiagen will post 1.25 earnings per share for the current year.

A number of large investors have recently made changes to their positions in QGEN. Acrospire Investment Management LLC increased its holdings in shares of Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after purchasing an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Qiagen by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after purchasing an additional 20 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Qiagen by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after purchasing an additional 225 shares in the last quarter. Koch Industries Inc. purchased a new position in shares of Qiagen during the 2nd quarter valued at approximately $231,000. Finally, Hartford Investment Management Co. purchased a new stake in Qiagen in the 3rd quarter worth $231,000. 62.37% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Qiagen’s (QGEN) Buy Rating Reaffirmed at Deutsche Bank” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/01/qiagens-qgen-buy-rating-reaffirmed-at-deutsche-bank.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.